MoonLake Immunotherapeutics (MLTX) Receivables - Other (2021 - 2026)

MoonLake Immunotherapeutics' Receivables - Other history runs 6 years deep, the most recent figure standing at $5.8 million for Q1 2026.

• On a quarterly basis, Receivables - Other rose 92.87% year-over-year to $5.8 million in Q1 2026; TTM through Mar 2026 was $5.8 million, a 92.87% increase from a year earlier, with the FY2025 full-year figure at $4.9 million, up 71.2% from the prior year.
• Receivables - Other advanced to $5.8 million in Q1 2026 per MLTX's latest filing, from $847000.0 in the prior quarter.
• Across five years, Receivables - Other topped out at $5.8 million in Q1 2026 and bottomed at -$383407.0 in Q4 2022.
• The 5-year median for Receivables - Other is $720755.0 (2023), against an average of $1.5 million.
• Biggest YoY gain for Receivables - Other was 971.77% in 2022; the steepest drop was 357.71% in 2022.
• Year by year, Receivables - Other stood at -$383407.0 in 2022, then jumped by 187.73% to $336374.0 in 2023, then climbed by 29.62% to $436000.0 in 2024, then jumped by 94.27% to $847000.0 in 2025, then surged by 580.4% to $5.8 million in 2026.
• Per Business Quant, the three latest MLTX Receivables - Other figures stand at $5.8 million (Q1 2026), $847000.0 (Q4 2025), and $4.0 million (Q3 2025).